Market
Organization with highest Lenacapavir recipients by mid-2026?
2
Resolution / Starting Odds
Global Fund • 25%
PEPFAR • 25%
UNAIDS • 25%
WHO • 25%
Reports from Global Fund, PEPFAR, UNAIDS, and WHO
Story
Global Fund and PEPFAR to Distribute Lenacapavir, 100% Success Rate, to 2 Million People by 2026
Dec 17, 2024, 03:09 PM
A new long-acting preventive drug for HIV, known as Lenacapavir, is set to be distributed in the world's poorest countries by late 2025 or early 2026. This initiative is part of a coordinated effort by the Global Fund and PEPFAR, aiming to reach 2 million people with the drug, which has shown 100% success in trials. Health officials believe that this drug could significantly reduce global HIV infections and accelerate the fight against the virus by 2030.
View original story
Similar markets
Gilead Sciences • 25%
Global Fund • 25%
Other • 25%
PEPFAR • 25%
Other • 25%
South America • 25%
Southeast Asia • 25%
Sub-Saharan Africa • 25%
North America • 25%
Europe • 25%
Africa • 25%
Asia • 25%
UK • 25%
South Africa • 25%
Other • 25%
USA • 25%
Adolescents • 25%
Adults • 25%
Elderly • 25%
Pregnant women • 25%
Europe • 25%
Africa • 25%
Asia • 25%
North America • 25%
South Africa • 25%
Other • 25%
India • 25%
United States • 25%
1-4 countries • 25%
15 or more countries • 25%
10-14 countries • 25%
5-9 countries • 25%
Other • 25%
South Africa • 25%
United States • 25%
European Union • 25%
Hospitals • 25%
Pharmacies • 25%
Clinics • 25%
Community health programs • 25%
Africa • 25%
European Union • 25%
United States • 25%
Other • 25%
Less than 20% • 25%
40% to 60% • 25%
More than 60% • 25%
20% to 40% • 25%